IL-13 Inhibitors for Atopic Dermatitis

CE / CME

IL-13 Inhibitors for Atopic Dermatitis: Expert Guidance and Guideline Recommendations

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: March 25, 2025

Expiration: March 24, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 13-year-old girl with persistent moderate to severe AD presents with widespread erythema, intense pruritus, lichenification, and negative quality of life due to sleep disruption and poor school performance. Past medical history includes asthma. Current medications include topical corticosteroids plus systemic for severe flares and phototherapy; she is adherent to therapy. Laboratory results are as follows: IgE 2300 IU/mL, eosinophils 9.0%, CBC and LFTs within normal limits, and negative TB, Hep B and C screenings.

Considering the patient’s clinical presentation, history, and lab findings, which of the following factors most strongly support initiating an IL-13–targeting biologic therapy for her AD?